A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel

Unknown Phase 2 NCT02175446

Study Description

In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated activity, but no agent is clearly superior. Although some combinations of cytotoxic agents provide a small progression-free survival advantage, none has demonstrated an OS advantage, and toxicity is generally greater than for single agents. At present, there is no standard for this treatment setting. New treatments that could delay disease progression without systemic toxicity would represent a significant advancement.

Study Details

Registry ID:
NCT02175446
Conditions:
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Phase:
Phase 2
Target Enrollment:
61 participants
Start Date:
Age Range:
18–999 years
Gender:
Female
Healthy Volunteers:
No

Study Locations (17 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →